1673534-76-3 (PD-1-IN-1,CA-170)

PD-1-IN-1;CA-170;

PD-1-IN-1;PD-1-IN-1 free base;L-Threonine, N-[[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]amino]carbonyl]-;NSC799645;PDL1 inhibitor;(((S)-3-amino-1-(3-((R)-1-amino-2-hydroxyethyl)-1,2,4-oxadiazol-5-yl)-3-oxopropyl)carbamoyl)-L-threonine;CA-170;646MN6KQ16;NSC-799645;EX-A1918;L-Threonine, N-((((1S)-3-amino-1-(3-((1R)-1-amino-2-hydroxyethyl)-1,2,4-oxadiazol-5-yl)-3-oxopropyl)amino)carbonyl)-;(2S,3R)-2-(3-((S)-3-Amino-1-(3-((R)-1-amino-2-hydroxyethyl)-1,2,4-oxadiazol-5-yl)-3-oxopropyl)ureido)-3-hydroxybutanoic acid;AKOS040733982;MS-25689;CA-170 (AUPM-170);CA 170 [WHO-DD];G16017;HY-101093;Aurigene 1;DA-66528;CS-6240;GLXC-15291;SCHEMBL20863767;(2S,3R)-2-[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid;UNII-646MN6KQ16;1673534-76-3;

HFOBENSCBRZVSP-LKXGYXEUSA-N

1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4-,5+,6+,8+/m1/s1

O1C([C@]([H])(C([H])([H])C(N([H])[H])=O)N([H])C(N([H])[C@]([H])(C(=O)O[H])[C@@]([H])(C([H])([H])[H])O[H])=O)=NC([C@]([H])(C([H])([H])O[H])N([H])[H])=N1